One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma
Abstract
Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles. Two patients achieved a partial response (10%), and 17 patients (81%) had stable disease. The median progression-free survival was 5 months. The progression-free survival at 6 months was 48%.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Glioma Meta-analysis Trialists Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359: 1011–1018.
2.
MacDonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277–1280.
3.
Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572–2578.
4.
Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83: 588–593.
5.
Figueroa JA. Protracted cyclic administration of temozolomide is feasible. A phase I pharmacokinetic and pharmacodynamic study. Presented at the 36th Annual Meeting of the American Society of Clinical Oncology; May 20–23, 2000; New Orleans, LA.
6.
Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002; 20: 1383–1388.
7.
Jaeckle KA, Hess KR, Yung WKA, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol. 2003; 21: 2305–2311.
Information & Authors
Information
Published In
Copyright
© 2004.
Publication History
Received: September 8, 2003
Accepted: January 29, 2004
Published online: June 7, 2004
Published in issue: June 8, 2004
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology, Pharmaceutics, 17, 2, (142), (2025).https://doi.org/10.3390/pharmaceutics17020142
- Temozolomide – Just a Radiosensitizer?, Frontiers in Oncology, 12, (2022).https://doi.org/10.3389/fonc.2022.912821
- The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials, Critical Reviews in Oncology/Hematology, 169, (103540), (2022).https://doi.org/10.1016/j.critrevonc.2021.103540
- Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells, Cancers, 13, 24, (6287), (2021).https://doi.org/10.3390/cancers13246287
- Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses, Molecular Cancer Therapeutics, 20, 10, (1789-1799), (2021).https://doi.org/10.1158/1535-7163.MCT-21-0228
- Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications, Current Neuropharmacology, 19, 4, (513-537), (2021).https://doi.org/10.2174/1570159X18666200626204005
- Gliome, Klinische Neurologie, (997-1010), (2020).https://doi.org/10.1007/978-3-662-60676-6_86
- Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells, International Journal of Molecular Sciences, 21, 19, (7006), (2020).https://doi.org/10.3390/ijms21197006
- Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor, Journal of Neuro-Oncology, 151, 1, (55-62), (2020).https://doi.org/10.1007/s11060-020-03598-2
- Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme, Journal of Controlled Release, 324, (1-16), (2020).https://doi.org/10.1016/j.jconrel.2020.05.012
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.